Anaplastic Large Cell Lymphoma Completed Phase 2 Trials for Sorafenib (DB00398)

Also known as: Lymphomas, Anaplastic Large-Cell / Anaplastic large-cell lymphoma / Large cell (Ki-1+) lymphoma / Lymphoma, Large-Cell, Anaplastic / Anaplastic large cell lymphoma, CD30-positive

IndicationStatusPhase
DBCOND0028602 (Anaplastic Large Cell Lymphoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00131937Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's LymphomaTreatment
NCT00278382Sorafenib in Treating Patients With Recurrent Non-Hodgkin's LymphomaTreatment